Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study)

References

• Sequist LV , SoriaJC, GoldmanJWet al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med.372(18), 1700–1709 (2015).
   PubMed Web of Science ®Google Scholar
• Janne PA , YangJC, KimDWet al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med.372(18), 1689–1699 (2015).
   PubMed Web of Science ®Google Scholar
• Engelman JA , JannePA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res.14(10), 2895–2899 (2008).
   PubMed Web of Science ®Google Scholar
• Soria JC , OheY, VansteenkisteJet al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med.378(2), 113–125 (2018).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV , ParikhP, von PawelJet al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol.26(21), 3543–3551 (2008).
   PubMed Web of Science ®Google Scholar
• Okamoto I , AoeK, KatoTet al. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naive patients with advanced nonsquamous non-small-cell lung cancer. Invest. New Drugs31(5), 1275–1282 (2013).
   PubMed Web of Science ®Google Scholar
• Yoneshima Y , MoritaS, AndoMet al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J. Thorac. Oncol.16(9), 1523–1532 (2021).
   PubMed Web of Science ®Google Scholar
• Nokihara H , LuS, MokTSKet al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann. Oncol.28(11), 2698–2706 (2017).
   PubMed Web of Science ®Google Scholar
• Garon EB , CiuleanuTE, ArrietaOet al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet384(9944), 665–673 (2014).
   PubMed Web of Science ®Google Scholar
• Soria JC , WuYL, NakagawaKet al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol.16(8), 990–998 (2015).
   PubMed Web of Science ®Google Scholar
• Ballard P , YatesJW, YangZet al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin. Cancer Res.22(20), 5130–5140 (2016).
   PubMed Web of Science ®Google Scholar
• Rangachari D , YamaguchiN, VanderLaanPAet al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer88(1), 108–111 (2015).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Camidge DR , LeeEQ, LinNUet al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol.19(1), e20–e32 (2018).
   PubMed Web of Science ®Google Scholar
• Lin NU , LeeEQ, AoyamaHet al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol.16(6), e270–e278 (2015).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, AhnMJet al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med.376(7), 629–640 (2017).
   PubMed Web of Science ®Google Scholar
• Mok TSK , KimSW, WuYLet al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J. Clin. Oncol.35(36), 4027–4034 (2017).
   PubMed Web of Science ®Google Scholar
• Hosomi Y , MoritaS, SugawaraSet al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J. Clin. Oncol.38(2), 115–123 (2020).
   PubMed Web of Science ®Google Scholar
• Wu YL , TsuboiM, HeJet al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med.383(18), 1711–1723 (2020).
   PubMed Web of Science ®Google Scholar
• Planchard D , FengPH, KarasevaNet al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open6(5), 100271 (2021).
   PubMed Web of Science ®Google Scholar
• Okada M , TanakaK, AsahinaHet al. Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR. J. Clin. Oncol.36(Suppl. 15), e21073 (2018).
   Web of Science ®Google Scholar
• Saito R , SugawaraS, KoRet al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL study. Eur. J. Cancer185, 83–93 (2023).
   PubMed Web of Science ®Google Scholar